SCHEMBL2992017

SCHEMBL2992017

CC(C)(C)[Si](C)(C)O[C@H]1CC[C@H](N2CCCC(Cc3ccc(-c4cccnc4)cc3Cl)C2=O)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 2/20 0.36
CNR1 P21554 1/20 0.34
JAK2 O60674 1/20 0.34
CYP11B1 P15538 2/20 0.33
CYP11B2 P19099 2/20 0.33
CYP1A2 P05177 1/20 0.33
PSD A5PKW4 1/20 0.33
TNIK Q9UKE5 1/20 0.33
CHRNB1 P11230 2/20 0.33
CHRNB2 P17787 2/20 0.33
CHRNB4 P30926 2/20 0.33
CHRNA3 P32297 2/20 0.33
CHRNB3 Q05901 2/20 0.33
DYRK1A Q13627 2/20 0.32
WNT1 P04628 1/20 0.32
MCHR1 Q99705 1/20 0.32
CCR5 P51681 1/20 0.32
ROCK2 O75116 1/20 0.32
GRM2 Q14416 1/20 0.32
MKNK1 Q9BUB5 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2992014 1.00 MET (0.36) METCNR1JAK2CYP11B1CYP11B2
SCHEMBL2985639 0.85 CYP11B2 (0.35) METCNR1CYP11B1CYP11B2CYP1A2
SCHEMBL2985633 0.85 CYP11B2 (0.35) METCNR1CYP11B1CYP11B2CYP1A2
SCHEMBL2994371 0.85 CNR1 (0.43) CNR1CYP11B1CYP11B2CYP1A2MCHR1
SCHEMBL2985050 0.84 MKNK1 (0.38) CNR1JAK2CYP11B1CYP11B2CYP1A2
SCHEMBL2992049 0.84 MKNK1 (0.38) CNR1JAK2CYP11B1CYP11B2CYP1A2
SCHEMBL2985055 0.84 MKNK1 (0.38) CNR1JAK2CYP11B1CYP11B2CYP1A2
SCHEMBL2990649 0.83 HSD11B1 (0.31)
SCHEMBL2990651 0.83 HSD11B1 (0.31)
SCHEMBL4699026 0.81 HSD11B1 (0.35) METROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100184764-A1 CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2010-07-22 US disclosed
US-7713979-B2 Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2010-05-11 US disclosed
EP-1807072-B1 CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2009-01-07 EP disclosed
US-20080275043-A1 Cycloalkyl Lactam Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1 ELI LILLY AND COMPANY 2008-11-06 US disclosed
EP-1807072-A1 CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2007-07-18 EP disclosed
WO-2006049952-A1 CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2006-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275043-A1 Cycloalkyl Lactam Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1 HSD11B1, HSDL2, HSD17B1 MET 1836/4885CNR1 1591/4885JAK2 4674/4885
US-20100184764-A1 CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD17B1, HSD3B1 MET 3002/4885CNR1 1140/4885JAK2 4174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.